INDEX OF SUBJECTS FOR VOLUME 41

Abscess
  gram-positive anaerobic cocci, 36
  survival of staphylococci, 158
Acinetobacter baumannii
  typing, in nosocomial infection, 244
Actinobacillus actinomycetemcomitans
  bone resorbing activity, 197
  surface-associated material, 197
Adherence
  C. krusei to host surfaces, 250
  E. coli to epithelial cells, 279, 399
  E. coli to rubber, and fibronectin, 133
  S. flexneri to epithelial cells, 279
  staphylococci to plastic materials, 158
  and virulence of *E. coli*, 156
Aerobactin production, by *E. coli*, 127, 156
Agglutination, lectins by streptococci, 14, 324
Aggregation, platelets by *S. sanguis*, 10
Aminoglycoside-modifying enzymes, in *S. aureus*, 282
Ampicillin, in listeriosis, 160
Anaerobes
  gram-positive cocci: clinical significance, 36
  see also Bacteroides
Animal models
  of Crohn's disease, 86
  see also Mouse model: Rat model
Antibiotic resistance
  antibiogram-resistogram scheme for *S. aureus*, 430, 441
  β-lactamase genes of *Citrobacter* spp., 209
  cephalosporins, and *Citrobacter* spp., 209
  of *Listeria* spp., 160
  methicillin, and *S. aureus*, 282, 430, 441
  trimethoprim, and urinary pathogens, 343
Antibiotics and other antimicrobial substances
  ampicillin and *Listeria* spp., 160
  anti-mycobacterial drugs and Crohn's disease, 85
  antibiogram-resistogram typing scheme for *S. aureus*, 430, 441
  effects of subinhibitory concentrations, 279
  fosfomycin, single-dose treatment of cystitis, 293
  immune response to aztreonam-treated *E. coli*, 179
  penicillin and *Listeria* spp., 160
  rifampicin against mycobacteria, 85
  rifampicin, effects on *E. coli*, 279
  rifampicin, effects on *S. flexneri*, 279
  therapy in listeriosis, 160
  topical, and production of *S. aureus* TSST-1, 408
Antibodies
  against "e" antigen of hepatitis B, 374
  against *M. tuberculosis*, 173, 378
  against mycobacteria in Crohn's disease, 82
  against *S. typhimurium*, 20
  against *Salmonella* serotype Enteritidis, 29
  egg-yolk, 29
  see also Monoclonal antibodies
Antifungal activity, pentamidine against *C. albicans*, 95
Antigens
  of *B. pertussis*, 152
  in Crohn's disease, 74
  of *E. coli*, 139, 156
  in genetically modified *L. fermentum*, 272
  hepatitis B "e" antigen, 374
  of *Listeria* spp., 160
  of *M. tuberculosis*, 378
  mycobacterial, 74, 378
  of *P. gingivalis*, 349
  of *S. typhimurium*, 20
  staphylococcal, 158
  superantigens of staphylococci, 158
  synthetic peptides, 349
Aspergillus spp., oxygen requirements, 311
Aztreonam-treated *E. coli*, immune response, 179

Bacteraemia, *Listeria* spp., 160
Bacteriophage *see* Phage typing
Bacteroides
  B. fragilis, detection of enterotoxin, 191
  B. fragilis, plasmids, 191
  lipopolysaccharide, 45
  serum sensitivity, 45
Biochemical testing, differentiation of streptococci, 145
Biofilm model, 359
Bone resorption, bacteria-induced, 197
BOOKS RECEIVED
  Case Studies in Medical Microbiology (C. A. Mims, G. Irwin and M. Zuckerman), 369
  Chemical Disinfection in Hospitals (G. A. J. Ayliffe, D. Coates and P. N. Hoffman), 70
  Current Topics in Microbiology and Immunology, 185
  Rotaviruses (Edited by R. F. Ramig), 369
  HIV, AIDS and the Brain. Association for Research in Nervous and Mental Disease, vol 72 (Edited by R. W. Price and S. W. Perry), 148
  Medical Microbiology (C. M. Mims, J. H. L. Playfair, I. M. Roitt, D. Wakelin and R. Williams), 370
  Medical Microbiology. Second Edition (P. R. Murray, G. S. Kobayashi, M. A. Pfaller and K. S. Rosenthal), 369
  Parasitic Protozoa, 2nd edn, vol 6 (Edited by J. P. Kreier), 216
  Rickettsial and Chlamydial Diseases of Domestic Animals (Edited by Z. Woldehiwet and M. Ristic), 369
  Significance of Cytokines in the Treatment of Infectious Diseases, Progress in Medical Microbiology, vol 4 (Edited by U. Ullmann and A. Dalhoff), 216
  The Human Herpes Viruses (Edited by B. Roizman, R. J. Whitley and C. Lopez), 215
  Tuberculosis—Back to the Future (Edited by J. D. H. Porter and K. P. W. J. McAdam), 215
Bordetella pertussis
  antigenic modulation, 152
  antigens, 152
  epidemiology of pertussis, 152
  pathogenicity, 152
  PCR in diagnosis of infections, 51
  pertussis toxin, 152
  vaccines, 152
  virulence factors, 152
Burn patients, 264

Campylobacter jejuni
  cell culture assay for cytotoxins, 224
Candida
  C. albicans, antifungal therapy, 95
  C. albicans, effects of urokinase on growth, 264
  C. albicans, intra-oral candidosis, 95
  C. albicans, phagocytosis by neutrophils, 384
  C. albicans, rapid characterisation by PMS, 98
  C. krusei, adhesion to host surfaces, 250
  C. krusei, biology, 295
  C. krusei, clinical manifestations, 295
  C. krusei, epidemiology, 295
  C. krusei, pathogenicity, 295
  C. krusei, phagocytosis by neutrophils, 384
Capsule, of *H. influenzae*, 149
Cell culture
  adherence of *C. krusei*, 250
  adherence of *E. coli*, 279, 399
  assay of *C. jejuni* cytotoxin, 224
  detection of toxigenic *C. difficile*, 316
  virulence factors of *E. coli*, 279
  virulence factors of *S. flexneri*, 279
Cephalosporin resistance, and *Citrobacter* spp., 209
Chlamydia trachomatis
  epidemiology, 168
  in urogenital infections, 168

Chloramphenicol
  effects on *E. coli*, 279
  effects on *S. flexneri*, 279
Cholera toxin, 3
Citrobacter spp.
  ampC β-lactamase genes, 209
  molecular typing, 209
Clofazamine, and Crohn's disease, 85
Clostridia
  C. difficile, cytotoxin, 316, 319
  C. difficile, detection by ToxA test, 316
  C. difficile, in diarrhoeal disease, 316
  C. difficile, toxin production in defined medium, 319
  C. perfringens, food-poisoning, 405
  C. perfringens, lecithinase-negative, 405
Coagulase, and virulence of *S. aureus*, 259
Cocci, gram-positive anaerobes: clinical significance, 36
Colibacillosis, systemic, 156
Colicin production by *E. coli*, 127, 156
Complement, and serum sensitivity of *E. coli*, 139
Cough, rat model of pertussis, 152
Crohn's disease
  animal models, 86
  chemotherapy, 85
  epidemiology, 75
  related diseases, 77
  role of mycobacteria, 74
Culture media
  cytotoxicity assay for *C. jejuni*, 224
  defined, and toxin production by *C. difficile*, 319
  effects of urokinase on microbial growth, 264
  glycosidase activities of *S. intermedius*, 184
  influence on serum sensitivity of *Bacteroides* spp., 45
  selective for urinary pathogens, 389
Cyclospora
  epidemiology, 217
  infection in man, 217
  oocysts, 217
Cystic fibrosis, 106
Cystitis, 293
Cytochrome oxidase, in selective media, 389
Cytotoxic necrotising factor, 156
Cytotoxicity assay
  for *C. difficile*, 316
  for *C. jejuni*, 224
  for enterotoxigenic *B. fragilis*, 191
Cytotoxins
  of *C. difficile*, 316
  of *C. jejuni*, 224
  of *E. coli*, 156
  staphylococcal, 158

Dapsone, 85
Diarrhoea
  detection of enteroaggregative *E. coli*, 393, 399
  detection of toxigenic *C. difficile*, 316
  E. coli infections in farm animals, 156
  isolation of *Cyclospora*, 217
Dihydrofolate reductase, 343
DNA
  analysis: taxonomic implications, 371
  detection of *H. influenzae* strains, 149
  fingerprinting of *Salmonella* serogroup D1, 112
  genomic fingerprinting of *H. influenzae*, 63
  probes for detection of *E. coli*, 393, 399
  typing of mycobacteria in Crohn's disease, 81

Egg-yolk antibodies, 29
Eikenella corrodens
  bone resorbing activity, 197
  surface-associated material, 197
Electronmicroscopy
  adherence of *E. coli* to cell cultures, 399
  E. coli and phagocytes in biofilm model, 359
  scanning, 359, 399
  transmission, 359, 399
Electrophoresis
  pulsed-field gel, 120, 329
  see also SDS-PAGE

ELISA
  detection of hepatitis C, 220
  immunotyping of *N. meningitidis*, 236
  ToxA test for toxigenic *C. difficile*, 316
Endocarditis, *S. aureus* infection, 259
Enterobacteria
  rapid identification on selective media, 389
Enterotoxins
  of *B. fragilis*, 191
  of *E. coli*, 156
  staphylococcal, 158
Epidemiology
  of *C. krusei* infection, 295
  of Crohn's disease, 75
  of *Cyclospora*, 217
  of *E. coli* infections, 156
  of listeriosis, 160
  molecular, of *Salmonella* serogroup D1, 112
  of *P. cepacia* in cystic fibrosis, 106
  of pertussis, 152
  of urogenital *C. trachomatis* infection, 168
Epidermolytic toxin (exfoliatin), 158
Escherichia coli
  adherence, 133, 156
  aerobactin production, 127, 156
  antibiotic-exposed, immune response, 179
  antigens, 139, 156
  attaching and effacing (AEEC), 156
  cell-surface hydrophobicity, 127
  colicin production, 127, 156
  Curli, 156
  cytotoxic necrotising factor, 156
  cytotoxins, 156
  diarrhoeal disease in farm animals, 156
  effects of fibronectin on adherence, 133
  effects of subinhibitory concentrations of antimicrobial agents, 279
  enteroaggregative (EAggEC), 393, 399
  enteropathogenic (EPEC), 156
  enterotoxigenic (ETEC), 156
  epidemiology, 156
  fimbriae, 156
  gene probes, 393, 399
  haemolysin production, 127
  mannose-resistant haemagglutination, 127
  monoclonal antibodies, 179
  P fimbriae, 127
  pathogenicity, 156
  and phagocytes in biofilm model, 359
  plasmids, 127, 156, 393
  rapid identification on selective media, 389
  serum sensitivity, 127, 139, 156
  toxins, 156
  in urinary tract infections, 127, 389
  vaccines 156
  verocytotoxigenic (VTEC), 156
  virulence factors, 127, 156, 279
  zoonoses, 156
Ethambutol, and Crohn's disease, 85

Faeces
  detection of enterotoxigenic *B. fragilis*, 191
  detection of toxigenic *C. difficile*, 316
  isolation of *Cyclospora*, 217
Fatty acid modifying enzyme, 158
Fibronectin
  and adherence of *E. coli*, 133
  binding by *M. tuberculosis*, 378
Fimbriae
  of *E. coli*, 127, 156
  of *P. gingivalis*, 349
  of *Salmonella* serotype Enteritidis, 29
Food
  antigens in Crohn's disease, 76
  mycobacteria in, 78
Food-poisoning, and *C. perfringens*, 405
Fosfomycin
  single-dose treatment of cystitis, 293
Fumarate reductase, of *H. pylori*, 56

Fusarium spp.
in mycotic keratitis, 204
sterol content, 204
toxin production, 204

Genital tract infections, mucosal immune response, 272
β-Glucuronidase, in selective media, 389
Glycosidase, activities of *S. intermedius*, 184

Haemagglutination, mannose-resistant, and *E. coli*, 127
Haemagglutinin, of *B. pertussis*, 152
Haemolysin production
by *E. coli*, 127
staphylococcal, 158
Haemophilus influenzae
capsule, 149
genomic DNA fingerprinting, 63
meningitis, 149
outer-membrane proteins, 63
pathogenicity, 149
transferrin-binding system, 120
type b, 120
typing techniques, 149
vaccines, 149
virulence factors, 149
Haemorrhagic fever with renal syndrome (HFRS), 71
Hantavirus infection, 71
Hantavirus pulmonary syndrome (HPS), 71
Helicobacter pylori
fumarate reductase, 56
immunogenic protein, 56
Hepatitis viruses
assays of hepatitis "e" antigen and antibody, 374
hepatitis C, prevalence in organ donor pool, 220
hepatitis C, transmission by organ transplantation, 220
HIV infection, treatment of oral candidosis, 95
Hyaluronate, degradation by *S. intermedius*, 414
Hydrophobicity, of *E. coli*, 127

Immune response
to *aroA* mutant of *S. typhimurium*, 20
to aztreonam-treated *E. coli*, 179
to mycobacteria in Crohn's disease, 82
to *P. gingivalis* fimbrial protein, 349
Immunisation
against *B. pertussis*, 152
against genital tract diseases, 272
against *H. influenzae*, 149
farm animals against *E. coli*, 156
guinea-pigs against *M. tuberculosis*, 378
mice against *E. coli*, 179
mice against *Salmonella* serotype Enteritidis, 29
mice against *Salmonella* serotype Typhimurium, 20
mice and guinea-pigs against *P. gingivalis*, 349
mucosal, 272
passive, 29, 179
sheep against *S. typhimurium*, 20
Indole tests, and selective media, 389
Intestinal cells
mediator release by cholera toxin, 3
Isoniazid, and Crohn's disease, 85

Johne's disease, 78
Journal of Medical Microbiology—25 years on, 149

Kawasaki syndrome, 158
Keratomycosis, 204
Klebsiella pneumoniae
effects of urokinase on growth, 264
phage typing, 423

β-Lactamase, of *Citrobacter* spp., 209
Lactobacillus fermentum
colonisation of genital tract, 272
genetic modification, 272
in mucosal immunisation, 272
Lecithinase, production by *C perfringens*, 405
Lectin typing, of streptococci, 14, 324

Leukocidins, staphylococcal, 158
Lipo-oligosaccharides, of *N. meningitidis*, 236
Listeria spp.
antigens, 160
antimicrobial chemotherapy, 160
clinical aspects of human infection, 160
epidemiology, 160
pathogenicity, 160
taxonomy, 160
typing methods, 160
Listeriosis, 160

Media *see* Culture media
Meningitis
H. influenzae, 149
Listeria spp., 160
mumps virus, 1
N. meningitidis, 339
Methicillin, resistance of *S. aureus*, 282, 430, 441
Molecular systematics
development and application, 371
Monoclonal antibodies
against antibiotic-exposed *E. coli*, 179
against *C. difficile*, 316
against *M. tuberculosis*, 378
against mycobacteria, 82, 173, 378
against *N. meningitidis*, 236
Mouse model
immune response to *Salmonella* vaccine, 20
passive immunisation against *E. coli*, 179
passive immunisation against salmonellosis, 29
Mucin
and glycosidase activities of *S. intermedius*, 184
Mumps virus, 1
Mycobacteria
associated diseases, 77
M. paratuberculosis, in Crohn's disease, 78
M. paratuberculosis, in Johne's disease, 78
M. tuberculosis, fibronectin-binding, 378
M. tuberculosis, 66-kDa seroreactive protein, 173, 378
M. tuberculosis, monoclonal antibodies, 173, 378
presence in food, 78
role in Crohn's disease, 74
Mycotic keratitis, 204

Nalidixic acid
effects on *E. coli*, 279
effects on *S. flexneri*, 279
Neisseria meningitidis
lipo-oligosaccharide immunotyping, 236
monoclonal antibodies, 236
pharyngeal carriage and disease, 339
Nephropathia epidemica, 71
Neutrophils
phagocytosis of *C. albicans* and *C. krusei*, 384

Oocysts, of *Cyclospora*, 217
Oral infections
antifungal therapy in candidosis, 95
Organ transplantation, and hepatitis C, 220
Oxygen, requirements of *Aspergillus* spp., 311

Penicillin, in listeriosis, 160
Pentamidine
antifungal activity, and candidosis, 95
Peptostreptococcus spp., clinical significance, 36
Pertussis toxin, 152
Phage typing
K. pneumoniae, 423
Listeria spp., 160
S. aureus, 282
Phagocytosis
C. albicans by neutrophils, 384
C. krusei by neutrophils, 384
E. coli by polymorphonuclear leucocytes, 359
Phenylalanine deaminase, in selective media, 389
Plasmids
coded gene probe for *E. coli*, 393

in genetically modified *L. fermentum*, 272
profile analysis of enterotoxigenic *B. fragilis*, 191
profile analysis of *Salmonella* serogroup D1, 112
trimethoprim resistance of urinary pathogens, 343
virulence-associated, in *E. coli*, 127, 156
Platelets, aggregation by *S. sanguis*, 10
Polymerase chain reaction
ampC β-lactamase genes of *Citrobacter* spp., 209
detection of aminoglycoside-modifying enzymes in *S. aureus*, 282
detection of *H. influenzae* strains, 149
detection of hepatitis C, 220
detection of *S. mutans*, 231
in diagnosis of *B. pertussis* infections, 51
fingerprinting of *H. influenzae*, 63
typing of *A. baumannii*, 244
typing of *Listeria* spp., 160
Polymorphonuclear leucocytes (PMNL)
interaction with *E. coli* in biofilm model, 359
Porphyromonas gingivalis
fimbriae, 349
immune responses to synthetic peptides, 349
PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND, Supplement 1 (Vol. 41, July 1994)
Proteinase, effects on microbial growth, 264
Proteins
66-kDa seroreactive protein of *M. tuberculosis*, 173, 378
immune response to synthetic peptides, 349
immunogenic, of *H. pylori*, 56
outer-membrane, of *H. influenzae*, 63
transferrin-binding, of *H. influenzae*, 120
Proteus mirabilis
rapid identification on selective media, 389
in urinary tract infections, 389
Pseudomonas
P. aeruginosa, effects of urokinase on growth, 264
P. aeruginosa, rapid identification on selective media, 389
P. aeruginosa, in urinary tract infections, 389
P. cepacia, epidemiology in cystic fibrosis, 106
Pyrazinamide, and Crohn's disease, 85
Pyrolysis mass spectrometry
epidemiology of *P. cepacia*, 106
rapid characterisation of *C. albicans*, 98

Rabbit intestinal loop
mediator release by cholera toxin, 3
Rat model
coughing rat model of pertussis, 152
S. aureus endocarditis, 259
Restriction fragment length polymorphism analysis
of *H. influenzae*, 63
of *Y. enterocolitica*, 329
Ribotyping, *A. baumannii*, 244
Rifampicin
and Crohn's disease, 85
effects on *E. coli*, 279
effects on *S. flexneri*, 279

Salmonellae
16s rRNA gene, 112
fimbriae, 29
immune response to *aroA* mutants, 20
insertion sequence IS*200*, 112
molecular epidemiology, 112
passive immunisation against salmonellosis, 29
plasmid-profile analysis, 112
serogroup D1, 112
serotype Enteritidis, 29
serotype Typhimurium, 20
Salmonellosis, 20, 29
Salpingitis, 168
Scalded skin syndrome, 158
SDS-PAGE
whole-cell polypeptides of *P. cepacia*, 106
Serology
hepatitis C in organ transplantation, 220
Serotyping
K. pneumoniae, 423
Listeria spp., 160
Serum
in *C. jejuni* culture media, 224
sensitivity of *Bacteroides* spp., 45
sensitivity of *E. coli*, 127, 139, 156
Sheep, immune response to *Salmonella* vaccine, 20
Shigella flexneri
effects of subinhibitory concentrations of antimicrobial agents, 279
virulence factors, 279
Silver sulphadiazine
and *S. aureus* toxin production, 408
Slime production, by staphylococci, 158
Staphylococci
adherence to plastic materials, 158
antigens, 158
coagulase-negative, 158
fatty acid modifying enzyme (FAME), 158
haemolysins, 158
Kawasaki syndrome, 158
pathogenicity, 158
S. aureus, aminoglycoside-modifying enzymes, 282
S. aureus, antibiogram-resistogram typing scheme, 430, 441
S. aureus, effects of topical antimicrobial agents, 408
S. aureus, effects of urokinase on growth, 264
S. aureus, in endocarditis, 259
S. aureus, enterotoxins, 158
S. aureus, epidermolytic toxin, 158
S. aureus, haemolysins, 158
S. aureus, methicillin-resistant, 282, 430, 441
S. aureus, pathogenicity, 158
S. aureus, phage typing, 282
S. aureus, role of coagulase in pathogenesis, 259
S. aureus, scalded skin syndrome, 158
S. aureus, toxic shock syndrome, 158
S. aureus, toxic shock syndrome toxin-1, 158, 408
S. aureus, toxins, 158, 408
S. aureus, virulence factors, 158
slime production, 158
superantigens, 158
survival in abscesses, 158
toxins, 158
virulence factors, 158
Sterol content, of *Fusarium* spp., 204
Streptococci
β-haemolytic, 324
differentiation of groups C and G, 145
lectin typing, 14, 324
S. intermedius, degradation of hyaluronate, 414
S. intermedius, glycosidase activities, 184
"*S. milleri*", agglutination by lectins, 14
S. mutans, detection by PCR, 231
S. mutans, *spaP* gene, 231
S. sanguis, aggregation of platelets, 10
viridans, 231
Sulphasalazine, and Crohn's disease, 85

Taxonomy
of *Listeria* spp., 160
and molecular systematics, 371
mycobacteria implicated in Crohn's disease, 80
Tetracycline
effects on *E. coli*, 279
effects on *S. flexneri*, 279
Tissue culture *see* Cell culture
ToxA test, for *C. difficile*, 316
Toxic shock syndrome, 158
Toxins
of *C. difficile*, 319
cholera, 3
of *E. coli*, 156
of *Fusarium* spp., 204
pertussis, 152
of *S. aureus*, 158, 408
staphylococcal, 158, 408
Transferrin-binding system of *H. influenzae*, 120
Trimethoprim resistance, in urinary pathogens, 343

Urethritis, non-gonococcal, 168

Urinary tract infections
E. coli, 127
selective media for pathogens, 389
single-dose treatment of cystitis, 293
trimethoprim resistance of pathogens, 343
Urogenital infections, *C. trachomatis*, 168
Urokinase, effects on microbial growth, 264

Vaccines
against *B. pertussis*, 152
against *E. coli*, 156
against genital tract diseases, 272
against *H. influenzae*, 149
against mumps virus, 1
against *S. typhimurium*, 20
genetically modified *L. fermentum*, 272
Verocytotoxins, 156
Virulence factors
B. fragilis, 191
B. pertussis, 152
E. coli, 127, 156, 279
H. influenzae, 149
S. aureus, 259
S. flexneri, 279
staphylococcal, 158

Yersinia enterocolitica, characterisation by PFGE, 329

INDEX OF AUTHORS FOR VOLUME 41

AITCHISON T C, *see* NOLAN *et al.*, 95
AJIKI Y, *see* YASUDA *et al.*, 359
ALEKSIC STOJANKA, *see* SAKEN *et al.*, 329
ALLAN E, POXTON I R. The influence of growth medium on serum sensitivity of *Bacteroides* species, 45
AMATUCCI A M, *see* LUN *et al.*, 179
ANDERSSEN R, *see* YU *et al.*, 133
ANSMITS L M, *see* MANNING *et al.*, 10
AVISON M B, *see* JONES *et al.*, 209

BADDOUR L M, TAYIDI M M, WALKER E, MCDEVITT D, FOSTER T J. Virulence of coagulase-deficient mutants of *Staphylococcus aureus* in experimental endocarditis, 259
BAIRD G D *see* BRENNAN *et al.*, 20
BALDASSARRI L, *see* MORELLI *et al.*, 399
BARBER P, *see* MEGHJI *et al.*, 197
BARTOLAZZI A, *see* LUN *et al.*, 179
BEIGHTON D, *see* HOMER *et al.*, 184, 414
Belgian Study Group of Hospital Infections (GDEPIH/GOSPIZ), *see* VANHOOF *et al.*, 282
BENGMARK S, *see* YU *et al.*, 133
BENNETT M, HART C A. Hantavirus infection, 71
BENNETT P M, *see* JONES *et al.*, 209
BHAN M K, *see* DEBROY *et al.*, 393
BHAT D A, *see* DESHPANDE *et al.*, 173
BHAT DEEPASHREE A, *see* DESHPANDE *et al.*, 378
BIRKHOLZ S, KNIPP U, LEMMA E, KRÖGER A, OPFERKUCH W. Fumarate reductase of *Helicobacter pylori*—an immunogenic protein, 56
BOEUFGRAS J M *see* EFSTRATIOU *et al.*, 145
BOLLEN A, *see* MEADE AND BOLLEN, 51
BRENNAN F R, OLIVER J J, BAIRD G D. Differences in the immune responses of mice and sheep to an aromatic-dependent mutant of *Salmonella typhimurium*, 20
BRETT M M. Outbreaks of food-poisoning associated with lecithinase-negative *Clostridium perfringens*, 405
BRIGHT B D, *see* DEBROY *et al.*, 393
BURNENS A P, *see* STANLEY *et al.*, 112

CANDINAS D, JOLLER-JEMELKA HELEN I, SCHLUMPF R, WICKI A, MUTIMER D J, KEUSCH G, LARGIADÈR F. Hepatitis C RNA prevalence in a Western European organ donor pool and virus transmission by organ transplantation, 220
CANTU J, *see* PETERSON *et al.*, 3
CAPRIOLI A, *see* MORELLI *et al.*, 399
CASEMORE D P. Cyclospora: another "new" pathogen, 217
CERQUETTI MARINA, *see* PANTOSTI *et al.*, 191
CHOPRA A K, *see* PETERSON *et al.*, 3
CLERICI P, *see* SESSA *et al.*, 168
COLANGELI R, *see* PANTOSTI *et al.*, 191
COLEMAN D C, *see* ROSSNEY *et al.*, 430, 441
COLL P, *see* VILA *et al.*, 244
COLMAN G, *see* EFSTRATIOU *et al.*, 145
COLOMBO R, *see* SESSA *et al.*, 168
CONTENT J, *see* VANHOOF *et al.*, 282
COOKSON B D, *see* WHITE *et al.*, 98
CORKILL J E, SISSON P R, SMYTH A, DEVENEY J, FREEMAN R, SHEARS P, HEAF D, HART C A. Application of pyrolysis mass spectroscopy and SDS–PAGE in the study of the epidemiology of *Pseudomonas cepacia* in cystic fibrosis, 106
CURRAN R, HARDIE K R, TOWNER K J. Analysis by pulsed-field gel electrophoresis of insertion mutations in the transferrin-binding system of *Haemophilus influenzae* type b, 120

D'AMBROSIO F, *see* PANTOSTI *et al.*, 191
DAMDINSUREN ENKE, *see* JONES *et al.*, 209
DANKERT J, *see* SCHOLTEN *et al.*, 236
DEBROY CHITRIA, BRIGHT B D, WILSON R A, YEALY JEANNE, KUMAR R, BHAN M K. Plasmid-encoded DNA fragment developed as a specific gene probe for the identification of enteroaggregative *Escherichia coli*, 393
DEL PIANO M, *see* SESSA *et al.*, 168
DENEER H G, *see* PIERONI *et al.*, 423
DENNING D W, *see* HALL AND DENNING, 311
DESHPANDE R G, KHAN M B, BHAT D A, NAVALKAR R G. Purification and partial characterisation of a novel 66-kDa seroreactive protein of *Mycobacterium tuberculosis* $H_{37}Rv$, 173
DESHPANDE RAJASHRI G, KHAN MAHFUZ B, BHAT DEEPASHREE A, NAVALKAR R G. Skin reactivity and fibronectin-binding property of TB66 (66-kDa protein of *Mycobacterium tuberculosis*), 378
DEVENEY J, *see* CORKILL *et al.*, 106
DEVINE DEIDRE A, ROBERTS A P. K1, K5 and O antigens of *Escherichia coli* in relation to serum killing *via* the classical and alternative complement pathways, 139
DONALDSON F, *see* RICHARDSON AND DONALDSON, 384
DONELLI G, *see* MORELLI *et al.*, 399
DUERDEN B I. 25 Years on—an update on topics selected from the first volume of the *Journal*, 149
DUIM BIRGITTA, *see* VAN BELKUM *et al.*, 63
DUNCAN S, *see* PETERSON *et al.*, 3

EDWARDS-JONES VALERIE, FOSTER H A. The effect of topical antimicrobial agents on the production of toxic shock syndrome toxin-1, 408
EFSTRATIOU ANDROULLA, COLMAN G, HAHN G, TIMONEY J F, BOEUFGRAS J M, MONGET D. Biochemical differences among human and animal streptococci of Lancefield group C or group G, 145

FALBO V, *see* MORELLI *et al.*, 399
FALLA T, *see* JORDENS *et al.*, 149
FERNANDEZ E J, *see* ONO *et al.*, 231
FILADORO F, *see* LUN *et al.*, 179
FILKA J, *see* SIEGFRIED *et al.*, 127
FORSEY T. Mumps vaccines—current status, 1
FOSTER H A, *see* EDWARDS-JONES AND FOSTER, 408
FOSTER T J, *see* BADDOUR *et al.*, 259
FRAIOLI R, *see* LUN *et al.*, 179
FREEMAN R, *see* CORKILL *et al.*, 106
FREEMAN R, *see* WHITE *et al.*, 98
FUKUI K, *see* ONO *et al.*, 231

GEMMELL C G. Staphylococcal aggressins and disease—the last 25 years, 158
GEYELIN A J, *see* MANNING *et al.*, 10
GIAMMANCO G, PIGNATO SARINA. Rapid identification of micro-organisms from urinary tract infections by β-glucuronidase, phenylalanine deaminase, cytochrome oxidase and indole tests on isolation media, 389
GODARD CLAUDINE, *see* VANHOOF *et al.*, 282
GORDINI C, *see* SESSA *et al.*, 168
GREEN G A, *see* SCHUÉ *et al.*, 316
GREENWOOD D. Fosfomycin trometamol and the single-dose treatment of cystitis, 293
GROOTVELD M C, *see* HOMER *et al.*, 414

HAFNER L M, *see* RUSH *et al.*, 272
HAHN G, *see* EFSTRATIOU *et al.*, 145
HALL LINDA A, DENNING D W. Oxygen requirements of *Aspergillus* species, 311
HANNECART-POKORNI ELEONORA, *see* VANHOOF *et al.*, 282
HARDIE K R, *see* CURRAN *et al.*, 120
HART C A, *see* BENNETT AND HART, 71
HART C A, *see* CORKILL *et al.*, 106
HART D A, WOODS D E. Human urokinase, a serine proteinase

potentiates the in-vitro growth of micro-organisms which commonly infect burn patients, 264
HAWKES J, *see* HOMER *et al.*, 414
HEAF D, *see* CORKILL *et al.*, 106
HEESEMANN J, *see* SAKEN *et al.*, 329
HENDERSON B, *see* MEGHJI *et al.*, 197
HILLYEAR J K, *see* YOUNG AND HILLYEAR, 343
HIROTA K, *see* ONO *et al.*, 231
HOMER K A, GROOTVELD M C, HAWKES J, NAUGHTON D P, BEIGHTON D. Degradation of hyaluronate by *Streptococcus intermedius* strain UNS35, 414
HOMER K A, WHILEY R A, BEIGHTON D. Production of specific glycosidase activities by *Streptococcus intermedius* strain UNS35 grown in the presence of mucin, 184
HOWELL S A, *see* RAZA *et al.*, 204

IKEMORI Y, *see* PERALTA *et al.*, 29
ITOH K, *see* MISAWA *et al.*, 224

JACOBS J A, *see* KELLENS *et al.*, 14
JAKAB ERSZÉBET, *see* YU *et al.*, 133
JIMENEZ DE ANTA T, *see* VILA *et al.*, 244
JOLLER-JEMELKA HELEN I, *see* CANDINAS *et al.*, 220
JONES C, *see* STANLEY *et al.*, 112
JONES M E, AVISON M B, DAMDINSUREN ENKE, MACGOWAN A P, BENNETT P M. Heterogeneity at the β-lactamase structural gene *ampC* amongst *Citrobacter* spp. assessed by polymerase chain reaction analysis: potential for typing at a molecular level, 209
JORDENS J ZOE, FALLA T, SLACK MARY P E. *Haemophilus influenzae*—the past, the present and the future, 149

KAMIYA S, *see* YAMAKAWA *et al.*, 319
KARASAWA T, *see* YAMAKAWA *et al.*, 319
KEANE C T, *see* ROSSNEY *et al.*, 430, 441
KELLENS J T C, JACOBS J A, PEUMANS W J, STOBBERINGH ELLEN E. Agglutination of "*Streptococcus milleri*" by lectins, 14
KEUSCH G, *see* CANDINAS *et al.*, 220
KHAN M B, *see* DESHPANDE *et al.*, 173
KHAN MAHFUZ B, *see* DESHPANDE *et al.*, 378
KMEŤOVÁ MARTA, *see* SIEGFRIED *et al.*, 127
KNIPP U, *see* BIRKHOLZ *et al.*, 56
KNOX K W, *see* MANNING *et al.*, 10
KODAMA Y, *see* PERALTA *et al.*, 29
KRÖGER A, *see* BIRKHOLZ *et al.*, 56
KUIPERS B, *see* SCHOLTEN *et al.*, 236
KUMAR R, *see* DEBROY *et al.*, 393
KUROKI M, *see* PERALTA *et al.*, 29

LAMEY P-J, *see* NOLAN *et al.*, 95
LARGIADÈR F, *see* CANDINAS *et al.*, 220
LATINO M A, *see* SESSA *et al.*, 168
LEMMA E, *see* BIRKHOLZ *et al.*, 56
LIND INGA, *see* WEIS AND LIND, 339
LJUNGH ÅSA, *see* YU *et al.*, 133
LLOVET T, *see* VILA *et al.*, 244
LLOVO J, *see* MUÑOZ *et al.*, 324
LOPEZ A, *see* MUÑOZ *et al.*, 324
LU YING, *see* PETERSON *et al.*, 3
LUN M T, AMATUCCI A M, RAPONI G, FILADORO F, BARTOLAZZI A, FRAIOLI R, NATALI P G, MANCINI C. Murine monoclonal antibody elicited with antibiotic-exposed *Escherichia coli* exerts protective capacity in experimental bacterial infections, 179

MCDEVITT D, *see* BADDOUR *et al.*, 259
MACFARLANE T W, *see* NOLAN *et al.*, 95
MACGOWAN A P, *see* JONES *et al.*, 209
MACGOWAN A P. *Listeria* spp. and listeriosis—25 years on, 160
MCLAREN I M, *see* WRAY *et al.*, 156
MAGLIANO E M, *see* SESSA *et al.*, 168
MALLET A I, *see* RAZA *et al.*, 204
MANCINI C, *see* LUN *et al.*, 179
MANNING J E, GEYELIN A J, ANSMITS L M, OAKEY H J, KNOX K W. A comparative study of the aggregation of human, rat and rabbit platelets by members of the *Streptococcus sanguis* group, 10
MARCOS A, *see* VILA *et al.*, 244
MEADE B D, BOLLEN A. Recommendations for use of the polymerase chain reaction in the diagnosis of *Bordetella pertussis* infections, 51
MEGHJI S, WILSON M, BARBER P, HENDERSON B. Bone resorbing activity of surface-associated material from *Actinobacillus actinomycetemcomitans* and *Eikenella corrodens*, 197
MENG X Q, *see* YAMAKAWA *et al.*, 319
MISAWA N, OHNISHI T, ITOH K, TAKAHASHI E. Development of a tissue culture assay system for *Campylobacter jejuni* cytotoxin and the influence of culture conditions on cytotoxin production, 224
MITCHELMORE I J, *see* MURDOCH *et al.*, 36
MÖLLER LIEKE, *see* VAN BELKUM *et al.*, 63
MOLOKÁČOVÁ MARIA, *see* SIEGFRIED *et al.*, 127
MONGET D, *see* EFSTRATIOU *et al.*, 145
MONTEIL H, *see* SCHUÉ *et al.*, 316
MORELLI R, BALDASSARRI L, FALBO V, DONELLI G, CAPRIOLI A. Detection of enteroadherent *Escherichia coli* associated with diarrhoea in Italy, 399
MUÑOZ A, LOPEZ A, LLOVO J. Lectin typing of β-haemolytic streptococci of groups A and B, 324
MURDOCH D A, MITCHELMORE I J, TABAQCHALI S. The clinical importance of gram-positive anaerobic cocci isolated at St Bartholomew's Hospital, London, in 1987, 36
MUTIMER D J, *see* CANDINAS *et al.*, 220

NAKAMURA S, *see* YAMAKAWA *et al.*, 319
NATALI P G, *see* LUN *et al.*, 179
NAUGHTON D P, *see* HOMER *et al.*, 414
NAVALKAR R G, *see* DESHPANDE *et al.*, 173, 378
NEMOTO K, *see* ONO *et al.*, 231
NICOSIA R, *see* SESSA *et al.*, 168
NOLAN ANITA, LAMEY P-J, MACFARLANE T W, AITCHISON T C, SHAW J, SIREL J Y. The effect of nebulised pentamidine on the concentration of intra-oral *Candida albicans* in HIV-infected patients, 95
NORMAN LARISA L, *see* TETZ AND NORMAN, 279
NYSSEN H J, *see* VANHOOF *et al.*, 282

OAKEY H J, *see* MANNING *et al.*, 10
OGAWA T. The potential protective immune responses to synthetic peptides containing conserved epitopes of *Porphyromonas gingivalis* fimbrial protein, 349
OHNISHI T, *see* MISAWA *et al.*, 224
OLIVER J J, *see* BRENNAN *et al.*, 20
ONO T, HIROTA K, NEMOTO K, FERNANDEZ E J, OTA F, FUKUI K. Detection of *Streptococcus mutans* by PCR amplification of *spaP* gene, 231
OPFERKUCH W, *see* BIRKHOLZ *et al.*, 56
OTA F, *see* ONO *et al.*, 231
OYAMA J, *see* YASUDA *et al.*, 359

PANTOSTI ANNALISA, CERQUETTI MARINA, COLANGELI R, D'AMBROSIO F. Detection of intestinal and extra-intestinal strains of enterotoxigenic *Bacteroides fragilis* by the HT-29 cytotoxicity assay, 191
PARR ANGELA, *see* WESTMORELAND *et al.*, 374
PARTON R. *Bordetella pertussis*—25 years on, 152
PENNINGTON T H. Molecular systematics and traditional medical microbiologists—problems and solutions, 371
PERALTA R C, YOKOYAMA H, IKEMORI Y, KUROKI M, KODAMA Y. Passive immunisation against experimental salmonellosis in mice by orally administered hen egg-yolk antibodies specific for 14-kDa fimbriae of *Salmonella* Enteritidis, 29
PETERSON J W, LU YING, DUNCAN S, CANTU J, CHOPRA A K. Interactions of intestinal mediators in the mode of action of cholera toxin, 3
PEUMANS W J, *see* KELLENS *et al.*, 14
PIERONI P, RENNIE R P, ZIOLA B, DENEER H G. The use of bacteriophages to differentiate serologically cross-reactive isolates of *Klebsiella pneumoniae*, 423
PIGNATO SARINA, *see* GIAMMANCO AND PIGNATO, 389

POOLMAN J T, *see* SCHOLTEN *et al.*, 236
POWELL N, *see* STANLEY *et al.*, 112
POXTON I R, *see* ALLAN AND POXTON, 45
PUSTORINO R, *see* SESSA *et al.*, 168
PUZOVÁ HANA, *see* SIEGFRIED *et al.*, 127

QUINT WIM, *see* VAN BELKUM *et al.*, 63

RAPONI G, *see* LUN *et al.*, 179
RAZA S K, MALLET A I, HOWELL S A, THOMAS P A. An in-vitro study of the sterol content and toxin production of *Fusarium* isolates from mycotic keratitis, 204
REGELINK ANNETTE, *see* VAN BELKUM *et al.*, 63
RENNIE R P, *see* PIERONI *et al.*, 423
RICHARDSON M D, DONALDSON F. Interaction of *Candida krusei* with human neutrophils *in vitro*, 384
ROBERTS A P, *see* DEVINE AND ROBERTS, 139
ROGGENKAMP A, *see* SAKEN *et al.*, 329
ROSSNEY A S, COLEMAN D C, KEANE C T. Antibiogram-resistogram typing scheme for methicillin-resistant *Staphylococcus aureus*, 430
ROSSNEY A S, COLEMAN D C, KEANE C T. Evaluation of an antibiogram-resistogram typing scheme for methicillin-resistant *Staphylococcus aureus*, 441
RUSH C M, HAFNER L M, TIMMS P. Genetic modification of a vaginal strain of *Lactobacillus fermentum* and its maintenance within the reproductive tract after intravaginal administration, 272

SAKEN ELIZABETH, ROGGENKAMP A, ALEKSIC STOJANKA, HEESEMANN J. Characterisation of pathogenic *Yersinia enterocolitica* serogroups by pulsed-field gel electrophoresis of genomic *Not*I restriction fragments, 329
SAMARANAYAKE L P, *see* SAMARANAYAKE AND SAMARANAYAKE, 295
SAMARANAYAKE L P, *see* SAMARANAYAKE *et al.*, 250
SAMARANAYAKE Y H, WU P C, SAMARANAYAKE L P, SO M, YUEN K Y. Adhesion and colonisation of *Candida krusei* on host surfaces, 250
SAMARANAYAKE YUTHIKA H, SAMARANAYAKE L P. *Candida krusei*: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen, 295
SANTINO I, *see* SESSA *et al.*, 168
SCHLUMPF R, *see* CANDINAS *et al.*, 220
SCHOLTEN R J P M, KUIPERS B, VALKENBURG H A, DANKERT J, ZOLLINGER W D, POOLMAN J T. Lipo-oligosaccharide immunotyping of *Neisseria meningitidis* by a whole-cell ELISA with monoclonal antibodies, 236
SCHUÉ V, GREEN G A, MONTEIL H. Comparison of the ToxA test with cytotoxicity assay and culture for the detection of *Clostridium difficile*-associated diarrhoeal disease, 316
SESSA R, LATINO M A, MAGLIANO E M, NICOSIA R, PUSTORINO R, SANTINO I, GORDINI C, CLERICI P, COLOMBO R, DEL PIANO M. Epidemiology of urogenital infections caused by *Chlamydia trachomatis* and outline of characteristic features of patients at risk, 168
SHAW J, *see* NOLAN *et al.*, 95
SHEARS P, *see* CORKILL *et al.*, 106
SIEGFRIED L, KMEŤOVÁ MARTA, PUZOVÁ HANA, MOLOKÁČOVÁ MARIA, FILKA J. Virulence-associated factors in *Escherichia coli* strains isolated from children with urinary tract infections, 127
SIREL J Y, *see* NOLAN *et al.*, 95
SISSON P R, *see* CORKILL *et al.*, 106
SISSON P R, *see* WHITE *et al.*, 98
SLACK MARY P E, *see* JORDENS *et al.*, 149
SMYTH A, *see* CORKILL *et al.*, 106
SO M, *see* SAMARANAYAKE *et al.*, 250
STANLEY J, POWELL N, JONES C, BURNENS A P. A framework for IS*200*, 16S rRNA gene and plasmid-profile analysis in *Salmonella* serogroup D1, 112
STOBBERINGH ELLEN E, *see* KELLENS *et al.*, 14

TABAQCHALI S, *see* MURDOCH *et al.*, 36
TAKAHASHI E, *see* MISAWA *et al.*, 224
TAYIDI M M, *see* BADDOUR *et al.*, 259
TETZ V V, NORMAN LARISA L. Effect of subinhibitory concentrations of antimicrobial agents on virulence factors of *Shigella flexneri* 2a and *Escherichia coli* O124, 279
THOMAS AMANDA J, *see* WESTMORELAND *et al.*, 374
THOMAS P A, *see* RAZA *et al.*, 204
THOMPSON DAPHNE E. The role of mycobacteria in Crohn's disease, 74
TIMMS P, *see* RUSH *et al.*, 272
TIMONEY J F, *see* EFSTRATIOU *et al.*, 145
TOWNER K J, *see* CURRAN *et al.*, 120

VALKENBURG H A, *see* SCHOLTEN *et al.*, 236
VAN ALPHEN L, *see* VAN BELKUM *et al.*, 63
VAN BELKUM A, DUIM BIRGITTA, REGELINK ANNETTE, MÖLLER LIEKE, QUINT WIM, VAN ALPHEN L. Genomic DNA fingerprinting of clinical *Haemophilus influenzae* isolates by polymerase chain reaction amplification: comparison with major outer-membrane protein and restriction fragment length polymorphism analysis, 63
VANHOOF R, GODARD CLAUDINE, CONTENT J, NYSSEN H J, HANNECART-POKORNI ELEONORA, Belgian Study Group of Hospital Infections (GDEPIH/GOSPIZ). Detection by polymerase chain reaction of genes encoding aminoglycoside-modifying enzymes in methicillin-resistant *Staphylococcus aureus* isolates of epidemic phage types, 282
VILA J, MARCOS A, LLOVET T, COLL P, JIMENEZ DE ANTA T. A comparative study of ribotyping and arbitrarily primed polymerase chain reaction for investigation of hospital outbreaks of *Acinetobacter baumanii* infection, 244

WADSTRÖM T, *see* YU *et al.*, 133
WALKER E, *see* BADDOUR *et al.*, 259
WEIS NINA, LIND INGA. Pharyngeal carriage of *Neisseria meningitidis* before and after treatment of meningococcal disease, 339
WESTMORELAND DIANA, PARR ANGELA, THOMAS AMANDA J. Assessment of hepatitis "e" antigen and "e" antibody status—tests of status or status of tests?, 374
WHILEY R A, *see* HOMER *et al.*, 184
WHITE G C, SISSON P R, FREEMAN R, COOKSON B D. Rapid characterisation of *Candida albicans* by pyrolysis mass spectrometry, 98
WICKI A, *see* CANDINAS *et al.*, 220
WILSON M, *see* MEGHJI *et al.*, 197
WILSON R A, *see* DEBROY *et al.*, 393
WOODS D E, *see* HART AND WOODS, 264
WOODWARD M J, *see* WRAY *et al.*, 156
WRAY C, WOODWARD M J, MCLAREN I M. *Escherichia coli* infection in farm animals—25 years of progress, 156
WU P C, *see* SAMARANAYAKE *et al.*, 250

YAMAKAWA K, KAMIYA S, MENG X Q, KARASAWA T, NAKAMURA S. Toxin production by *Clostridium difficile* in a defined medium with limited amino acids, 319
YASUDA H, AJIKI Y, OYAMA J, YOKOTA T. Interaction between human polymorphonuclear leucocytes and bacteria released from in-vitro bacterial biofilm models, 359
YEALY JEANNE, *see* DEBROY *et al.*, 393
YOKOTA T, *see* YASUDA *et al.*, 359
YOKOYAMA H, *see* PERALTA *et al.*, 29
YOUNG HILARY-KAY, HILLYEAR J K. Trimethoprim resistance in urinary pathogens in northern Scotland: epidemic spread of a resistance plasmid encoding the type Ib trimethoprim-resistant dihydrofolate reductase, 343
YU J L, LJUNGH ÅSA, ANDERSSEN R, JAKAB ERSZÉBET, BENGMARK S, WADSTRÖM T. Promotion of *Escherichia coli* adherence to rubber slices by adsorbed fibronectin, 133
YUEN K Y *see* SAMARANAYAKE *et al.*, 250

ZIOLA B, *see* PIERONI *et al.*, 423
ZOLLINGER W D, *see* SCHOLTEN *et al.*, 236